阿普唑仑(Alprazolam) - 药物靶点：DOCK5 x GABAA receptor_在研适应症：焦虑，紧张症，抑郁症_专利_临床

概要

基本信息

简介阿普唑仑是一种小分子药物，可作为 GABAA 受体的激动剂，GABAA 受体是一种对抑制性神经递质γ-氨基丁酸 (GABA) 有反应的神经递质受体。通过增强 GABA 在大脑中的作用，阿普唑仑具有抗焦虑、镇静和抗惊厥的特性。这种药物主要用于治疗焦虑症和恐慌症。然而，它也被发现对某些癫痫和哮喘相关焦虑症有效。阿普唑仑于1981年10月16日首次获得FDA批准，由日本制药公司武田制药公司研制。阿普唑仑有多种形式，包括速释片和缓释片，以及口服溶液。应谨慎使用，因为它可能会导致依赖性和戒断症状。

药物类型

小分子化药

别名

8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine、Alprazolcem、AP-1002

+ [16]

靶点

DOCK5 x GABAA receptor

作用机制

DOCK5抑制剂(dedicator of cytokinesis 5 inhibitors)、GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

焦虑紧张症抑郁症+ [5]

非在研适应症

药物滥用轻度哮喘恐慌

原研机构

Takeda Pharmaceutical Co., Ltd.Upjohn Pharmaceuticals Ltd.

在研机构

UCB SAUpjohn US 2 LLC

优时比贸易（上海）有限公司

+ [6]

非在研机构

Engage Therapeutics, Inc.初创企业

UCB, Inc.

UCB Pharma GmbH

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1981-10-16),

焦虑症惊恐障碍

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (中国)

登录后查看首次获批时间轴

结构

分子式C17H13ClN4

InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N

CAS号28981-97-7

关联

113

项与阿普唑仑相关的临床试验

NCT06293638 / RecruitingN/A

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will be asked to remain seated with their head inside of a Magnetoencephalography (MEG) recording system as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation.

开始日期2024-03-25

申办/合作机构

The Cleveland Clinic Foundation

NCT05006079 / Recruiting临床2期IIT

Opioid/Benzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies - Study 3

In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.

开始日期2024-03-13

申办/合作机构

Wayne State University (Michigan)

[+1]

NCT06357104 / Completed临床4期IIT

Detoxification From the Lipid Tract by Cocktail Design

Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid (GABA) stimulation. The cocktail therapy starts after the primary efficacy endpoint, and concomitant therapy is adopted throughout the study.

开始日期2024-02-26

申办/合作机构

重庆医科大学附属第一医院

100 项与阿普唑仑相关的临床结果

登录后查看更多信息

100 项与阿普唑仑相关的转化医学

登录后查看更多信息

100 项与阿普唑仑相关的专利（医药）

登录后查看更多信息

2,597

项与阿普唑仑相关的文献（医药）

2024-04-01·JAMA psychiatry

Benzodiazepine Use During Pregnancy and Risk of Miscarriage

Article

作者: Meng, Lin-Chieh ; Chuang, Hui-Min ; Hsiao, Fei-Yuan ; Lin, Chih-Wan ; Chen, Liang-Kung

Importance:

Benzodiazepine use during pregnancy has raised significant concerns due to the potential harmful effects of this drug class on neonates. Studies on the association between benzodiazepine use and the risk of miscarriage are limited.

Objective:

To quantify the risk of miscarriage associated with benzodiazepine use during pregnancy after controlling for unmeasured confounders and exposure time trends.

Design, Setting, and Participants:

This was a nationwide, population-based case-time-control study using Taiwan’s National Birth Certificate Application database and the National Health Insurance database. Pregnancies resulting in miscarriage between 2004 and 2018 were included in the case group and were 1:1 matched with exposure time-trend control individuals using disease risk score, considering demographic characteristics and prepregnancy comorbidities. Data were analyzed from August 2022 to March 2023.

Exposures:

Discordant exposures to benzodiazepines during risk period (1-28 days before miscarriage) and 2 reference periods (31-58 days and 181-208 days before the last menstrual period) were compared for each pregnancy.

Main Outcomes and Measures:

Miscarriage was defined as any pregnancy loss occurring between the first prenatal care visit (usually 8 weeks) and the 19th completed week of pregnancy.

Results:

This study comprised a total of 3 067 122 pregnancies among 1 957 601 women, 136 134 of which (4.4%) resulted in miscarriage. The mean (SD) age of the study population was 30.61 (5.91) years. The use of benzodiazepines during pregnancy was associated with an increased risk of miscarriage (odds ratio [OR], 1.69; 95% CI, 1.52-1.87), and consistent findings were observed across multiple sensitivity analyses considering different time windows and accounting for misclassification. In subgroup analyses, an increased risk of miscarriage was associated with each commonly used individual benzodiazepine, ranging from case-time-control ORs of 1.39 (95% CI, 1.17-1.66) for alprazolam to 2.52 (95% CI, 1.89-3.36) for fludiazepam.

Conclusions and Relevance:

This nationwide case-time-control study revealed an increased risk of miscarriage associated with benzodiazepine use during pregnancy after accounting for measurable confounders, and results were unlikely to be due to unmeasured confounding. These findings underscore the necessity for health care professionals to meticulously balance the risk-benefit ratio when considering the use of benzodiazepines to treat psychiatric and sleep disorders during pregnancy.

2024-03-15·The Journal of the American Academy of Orthopaedic Surgeons

Treatment of Concurrent Depression and Its Effect on Outcomes After Total Joint Arthroplasty: A Systematic Review of Comparative Studies

Review

作者: Kruse, Colin ; Wolfstadt, Jesse ; Morgan, Samuel B ; Ekhtiari, Seper ; Zywiel, Michael ; Shahabi, Ali

Purpose::

There is a growing body of evidence suggesting that patients with a diagnosis of depression suffer worse outcomes after total joint arthroplasty (TJA) procedures. It is unclear whether depression treatment is a modifiable risk factor that can be targeted to improve suboptimal outcomes. We conducted a systematic review to understand the role that various interventions have on outcomes of TJA in patients with diagnosed depression (PDDs).

Methods::

PubMed, Ovid MEDLINE, Scopus, and EMBASE were searched systematically from inception until November 2022. Studies of PDDs who underwent TJA that compared any intervention/treatment of depression with a control group and reported pain, functional outcomes, depression scores, and/or revision rates after TJA were relevant for this review.

Results::

Ten relevant studies were included in the final systematic review, with a total of 33,501 patients included. Two studies reported lower revision rates for patients receiving selective serotonin reuptake inhibitor treatment and psychotherapy. Two studies showed no difference in functional outcomes for patients receiving pharmacologic treatment. One study reported improved functional outcomes for patients receiving cognitive behavioral therapy and another reported improved postoperative functional outcomes for patients receiving alprazolam.

Conclusion::

Interventions targeted at PDDs may improve short-term pain and functional outcomes, and there may be an association between selective serotonin reuptake inhibitor use and implant survival. The current literature is limited and inconclusive, with important gaps in understanding regarding the optimization and treatment of this modifiable risk factor. Surgeons should consider depression treatment as a method to improve outcomes in this cohort.

2024-03-01·Value in health regional issues

Evolving Trends and Economic Burden of Benzodiazepine Use: Insights From a 10-Year Predictive Model

Article

作者: Marcec, Robert ; Koren, Luciana ; Likic, Robert ; Koren, Andro ; Marcinko, Darko

OBJECTIVES:

Benzodiazepines (BZDs) are widely prescribed in Croatia to treat anxiety, insomnia, mood disorders, and epileptic seizures. Long-term BZD use is associated with memory loss, Alzheimer's disease, dependence, addiction, falls in elderly populations, and increased traffic accident risk.

METHODS:

Drug consumption data were obtained from the Agency for Medicinal Products and Medical Devices of Croatia website. Autoregressive integrated moving average models, constructed using R programming language, forecasted diazepam, alprazolam, and overall BZD utilization and financial costs at a national level over 10 years.

RESULTS:

BZD consumption increased by up to 18.6% between 2012 and 2020. During the same period, diazepam utilization rose by 29.1%, and alprazolam consumption increased by 19.4%. Our model predicts that, by 2032, BZD, diazepam, and alprazolam utilization will increase substantially. The total projected financial expenditure for BZDs in 2032 is estimated at 14.22 million euros, with diazepam and alprazolam expenditures at 7.39 and 4.12 million euros, respectively. These increases will result in significant growth in healthcare spending and a rise in adverse effects related to long-term use.

CONCLUSIONS:

National healthcare decision makers should consider implementing regulatory and legislative measures to quantify, specify, and limit monthly BZD use for each patient. This would help control the negative side effects of prolonged BZD use while continuing to provide treatment for patients who genuinely need it.

65

项与阿普唑仑相关的新闻（医药）

2024-06-24

·GlobeNewswire-Health Care

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial. AKYNZEO injection (Ready-to-Use) is a new method of administration and contains the same formulation as the prior AKYNZEO Injection (To-be-Diluted). The features of the new ready-to-use presentation of AKYNZEO injection include: No reconstitution or dilution required; infuse directly from the vial using a built-in hanging strapNo refrigeration required at any point during distribution, storage, or preparationAccessible via automated dispensing machine, allowing the product to be stored and available near the location of patient care AKYNZEO injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin. It can be administered simultaneously with intravenous dexamethasone sodium phosphate. Dr. Melanie Rolli, Helsinn Group CEO, commented: “As a pioneer in cancer supportive care, Helsinn continues to be unwavering in our pursuit to help patients and clinicians in cancer care. We are very pleased to launch the new AKYNZEO Ready-to-Use vial, building on our legacy of innovation.” Ordering information Clinicians wishing to order the new vial should contact their GPO or distributor. The National Drug Code (NDC) number for AKYNZEO injection vial with hanger (Ready-to-Use) is 69639-106-01 and the J Code is J1454 (Injection, fosnetupitant 235 mg and palonosetron 0.25 mg); billing unit (single dose vial [SDV]). About AKYNZEO® AKYNZEO is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. A single dose of AKYNZEO given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days. INDICATION AKYNZEO (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use AKYNZEO injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. IMPORTANT SAFETY INFORMATION Warnings and Precautions Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs. Adverse Reactions Most common adverse reactions (≥3%) for AKYNZEO capsules are headache, asthenia, dyspepsia, fatigue, constipation and erythema. The safety profile of AKYNZEO injection was generally similar to AKYNZEO capsules. Drug Interactions Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days Dexamethasone doses should be reduced when given with AKYNZEO. A more than two- fold increase in the systemic exposure of dexamethasone was observed 4 days after a single infusion of fosnetupitant.Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased. Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO. Use in Specific Populations Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease.Advise women of potential risk to fetus; limited data are available; may cause fetal harm. For more information about AKYNZEO® please see the full US Prescribing Information. About Helsinn Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and an extensive network of long-standing trusted partners enabling a commercial presence in more than 90 countries. Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision. To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X. For more information: Helsinn Group Media Contact:Sabrina PerucchiGroup Communication ManagerLugano, Switzerland Tel: +41 (0) 91 985 21 21 Email: Info-hhc@helsinn.com

上市批准临床结果

2024-06-20

·BioSpace

Luxor Scientific Unveils Cutting-Edge Testing Solutions to Combat Escalating Illicit Drug Crisis

Greenville, SC June 20, 2024 – Luxor Scientific, a leader in scientific research, announces groundbreaking advancements in combatting the rise of deadly illicit drugs. Leveraging expertise in toxicology, Luxor has developed advanced testing solutions to address the nation’s overdose crises associated with substances like bromazolam, tianeptine, xylazine, and nitazenes, providing healthcare professionals the information needed to develop more effective treatment plans. Bromazolam, often labeled as 'Fake Xanax,' is misrepresented as genuine Xanax, leading to a surge in overdose incidents and widespread concern among healthcare and law enforcement. Consumed orally to alleviate anxiety and panic, bromazolam's availability online exacerbates the risk. Similarly, tianeptine, known as 'gas station heroin,' administered intravenously for a euphoric effect, has recently prompted Louisiana to ban it due to reports of seizures and loss of consciousness. Additionally, the emergence of xylazine, a potent horse tranquilizer mixed with fentanyl, exacerbates the crisis, causing zombie-like behavior in users. Luxor Scientific's innovative testing solutions mark a significant advancement in combating illicit drug proliferation, providing precise detection of hazardous substances in easily collected body fluids. Our commitment to updating our test menu ensures we stay ahead in addressing evolving drug trends. Using state-of-the-art technology and extensive toxicology experience, our testing protocols empower stakeholders to respond effectively, safeguarding public health. Detection of novel illicit drugs is exclusive to experienced labs like Luxor Scientific. Luxor’s ability to detect illicit drug use in urine and oral fluid, along with rapid turnaround times, ensures life-saving results within 24 to 48 hours, critical for immediate intervention in emergency situations. “As a leading force in scientific research and innovation, Luxor Scientific is committed to leveraging our expertise to address pressing societal challenges such as the proliferation of illicit drugs,” stated Dr. Marion Snyder, Chief Science Officer at Luxor Scientific. “Our cutting-edge testing solutions represent a significant milestone in our ongoing efforts to combat the devastating impact of substance use disorder, empowering communities with the tools needed to safeguard public health and effectively treat patients.” Luxor Scientific has the capability to detect over 100 drugs and metabolites, including novel illicits. With an unwavering mission towards scientific excellence and social responsibility, Luxor Scientific is dedicated to effecting positive change in the face of adversity. As communities grapple with the escalating threat posed by novel illicit drugs, Luxor Scientific stands ready to partner with stakeholders across sectors to confront this crisis head-on and build a safer, healthier future for all. Healthcare providers concerned they are not identifying all the illicit substances their patients could be consuming or co-addicted can email Luxor Scientific at clientservices@luxorscientific.org or call 864-568-8940. About Luxor Scientific Luxor Scientific was founded with the mission of providing better information faster. As a full-service privately-held CAP-accredited medical and research laboratory, Luxor offers a robust menu of clinical and anatomical testing services. Today, Luxor Scientific is one of the fastest-growing companies in the southeast, specializing in cutting-edge diagnostic testing solutions in the areas of metabolomics, genomics, toxicology and histology. Luxor’s industry-leading turnaround times and state-of-the-art equipment and diagnostic solutions, allows Luxor to provide personalized service, accurate testing, and innovative functional reporting. For more information about Luxor Scientific and our full test offering, please visit . Media Contact: Kristina Loughrey kristina@klcoms.com 864.360.5848

诊断试剂

2024-06-13

·Science Daily

Neural balance in the brain is associated with brain maturity and better cognitive ability

The E/I ratio of children decreases with healthy development. Children with a lower E/I ratio were observed to have better performance than their peers in cognitive tests such as memory and intelligence, according to researchers. In a world where external and internal stimuli can throw our entire body system off balance, how does our brain prevent itself from becoming overly stimulated? The answer lies in our brain's ability to maintain the balance of neural excitation (E) and inhibition (I), known as the E/I ratio. By regulating the E/I ratio, the brain prevents over-stimulation and under-stimulation. The E/I ratio of children decreases with healthy development. Children with a lower E/I ratio were observed to have better performance than their peers in cognitive tests such as memory and intelligence, according to studies by researchers from the Centre for Sleep and Cognition at the Yong Loo Lin School of Medicine (NUS Medicine). With the aim of drawing meaningful connections between E/I ratio and brain maturation, the study team, led by fourth-year PhD student Zhang Shaoshi, Associate Professor Thomas Yeo from the Centre for Sleep and Cognition at NUS Medicine, Assistant Professor Bart Larsen from the University of Minnesota and Associate Professor Theodore Satterthwaite from the University of Pennsylvania, looked at how E/I ratio changes in youths, by studying the MRI brain scans of 885 children, adolescents and young adults from the United States of America and 154 children from Singapore. E/I ratio is an aspect that is continually changing and developing throughout childhood and adolescence. The Singaporean data cohort were obtained from GUSTO, Singapore's largest and most comprehensive birth cohort study that seeks to help the next generation become healthier. Described as the Yin and Yang of the brain, researchers have found that too much excitation or excessive inhibition can be harmful, leading to a higher risk of developing brain disorders, such as autism, Alzheimer's disease and schizophrenia. In less severe situations, someone with too much excitation might overthink in social situations, resulting in anxiety. Indeed, a common drug for reducing anxiety symptoms is Xanax, which increases neural inhibition, thus reducing neural excitation. In more severe scenarios, over-excitation can cause an epileptic seizure. On the opposite end of the spectrum, too much inhibition indicates an absence of brain activity, effectively putting the person in a vegetative state. Therefore, inhibition is needed to balance excitation. Overall, a balanced E/I ratio is important for a well-functioning brain. Despite E/I's importance for brain health, it is hard to measure its ratio in the human brain without using invasive techniques. Therefore, the team developed a technique, combining artificial intelligence and biophysical modeling to infer E/I ratios from non-invasive, non-radioactive MRI scans. The team demonstrated the validity of their estimated E/I ratios through an experiment, during which participants ingested anti-anxiety medication (Xanax) or a placebo. The team's hypothesis is that once Xanax is ingested, inhibition will increase, so the overall E/I ratio decreases. To test this hypothesis, the research team scanned healthy individuals on two separate occasions. A participant is given Xanax before one MRI session and placebo in another MRI session. For some participants, Xanax might be administered in the first session, while for others Xanax might be administered in the second session. All parties involved in this experiment were not privy to whether an MRI session involved the placebo or the anti-anxiety drug. The team found that estimated E/I ratio markers were indeed lower after participants had ingested Xanax, compared with the placebo, and thus validating their technique. The study team then proceeded to use MRI brain scans to study brain development in a large sample of more than 1000 children, adolescents and young adults from Singapore and the United States of America. They discover that E/I ratios decrease with healthy development. Next, to establish the link between E/I ratios and cognitive function, the team divided participants, ranging from age 7 to 23, into high and low-performance groups based on their scores on certain cognitive tests. They found that the high performing groups had lower E/I ratios than their peers of the same age, suggesting that cognitive abilities improve as the E/I ratio matures during development. Beyond their study on neurodevelopment, the team is keen on applying their approach to gain mechanistic insights into various brain disorders, by studying how the E/I ratio differs between healthy participants and patients battling mental disorders. The team also aims to study how the E/I ratio changes as people age, to gain insights into neurodegenerative disorders, such as Alzheimer's Disease. Assoc Prof Thomas Yeo, who is also from the NUS College of Design and Engineering and Principal Investigator of this study, adds, "Our findings enhance our understanding of brain development and highlight potential avenues for understanding the emergence of psychopathology in youth. Hopefully, these findings will lead us to figure out which brain circuits get over-excited or over-inhibited easily, or pinpoint certain abnormal brain regions specific to an individual patient. This could shed more light on how medication or brain stimulation can be customised according to individuals, that would shape the course of treatment of brain disorders in the long run." This study is published in Proceedings of the National Academy of Sciences of the United States of America, titled 'In vivo whole-cortex marker of excitation-inhibition ratio indexes cortical maturation and cognitive ability in youth'.

100 项与阿普唑仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00225	阿普唑仑	N05BA12	DB00404

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
焦虑	日本	VIATRIS Pharmaceuticals Ltd.	1984-02-15
焦虑	日本	Teva Takeda Pharma Ltd.初创企业	1984-02-15
紧张症	日本	Teva Takeda Pharma Ltd.初创企业	1984-02-15
抑郁症	日本	VIATRIS Pharmaceuticals Ltd.	1984-02-15
抑郁症	日本	Teva Takeda Pharma Ltd.初创企业	1984-02-15
入睡和睡眠障碍	日本	Teva Takeda Pharma Ltd.初创企业	1984-02-15
入睡和睡眠障碍	日本	VIATRIS Pharmaceuticals Ltd.	1984-02-15
焦虑症	美国	Viatris, Inc.	1981-10-16
焦虑症	美国	Upjohn US 2 LLC	1981-10-16
惊恐障碍	美国	Upjohn US 2 LLC	1981-10-16
惊恐障碍	美国	Viatris, Inc.	1981-10-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
癫痫持续状态	临床3期	美国	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	中国	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	日本	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	澳大利亚	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	保加利亚	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	捷克	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	法国	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	德国	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	匈牙利	UCB Biopharma SRL	2021-12-07
癫痫持续状态	临床3期	意大利	UCB Biopharma SRL	2021-12-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04970342 (CTgov)	临床1期	-	13	Placebo (Lactose) Capsule+Cannabis (0%/ THC / 0% CBD) ("Sober" or Double Placebo)	願繭壓淵構願遞艱鏇壓(範鹽築願簾願壓製糧糧) = 糧製艱憲構遞淵襯選醖繭繭築簾蓋齋壓鬱獵鬱 (膚製願憲鹽壓夢襯鹹顧, 窪製壓觸顧簾顧糧積糧 ~ 網選鹽膚醖淵夢壓夢衊) 更多	-	2023-07-25
				Cannabis (0%/ THC / 0% CBD)+0.75 mg Alprazolam Capsule (Active Alprazolam (Xanax), Placebo Cannabis)	願繭壓淵構願遞艱鏇壓(範鹽築願簾願壓製糧糧) = 壓衊糧齋衊齋網膚窪鬱繭繭築簾蓋齋壓鬱獵鬱 (膚製願憲鹽壓夢襯鹹顧, 鹹蓋願夢網積廠鹹窪醖 ~ 範蓋鹹糧遞鹽鏇鑰遞獵) 更多
NCT03478982 (ENGAGE-E-001, Pubmed)	临床2期	癫痫	116	Staccato® alprazolam 1.0 mg	顧鹽醖衊淵鏇襯廠壓襯(構鹹壓蓋積範淵鏇選顧) = 鹽簾夢齋構鹹衊鬱蓋鬱壓積遞簾醖築醖鬱鹽獵 (選選夢夢糧製觸淵鹽鹹 )	-	2022-10-21
				Staccato® alprazolam 2.0 mg	顧鹽醖衊淵鏇襯廠壓襯(構鹹壓蓋積範淵鏇選顧) = 鑰構餘鏇鏇構選構夢顧壓積遞簾醖築醖鬱鹽獵 (選選夢夢糧製觸淵鹽鹹 )
NCT03478982 (P1.5-023, AAN2019)	临床2期	癫痫	8	Staccato Alprazolam 1 mg	壓壓艱窪鹽鏇淵夢窪製(鹽簾夢範糧鹽醖顧憲鹽) = no adverse events were serious or severe 積網鏇齋顧膚鏇壓蓋醖 (鹹廠遞範糧廠觸鹹膚鏇 )	积极	2019-04-09
NCT03447353 (CTgov)	临床4期	-	18	Placebo Oral Tablet ("Sober" or Double Placebo)	淵餘鹽鹽鬱蓋網構蓋糧(餘顧壓鬱糧衊憲餘壓餘) = 鏇範觸鑰構網廠醖範衊獵構製遞築遞餘觸顧簾 (糧顧襯夢窪壓鹹願衊簾, 顧繭淵築鹹艱顧顧獵醖 ~ 範網糧鏇製觸鬱淵憲壓) 更多	-	2018-09-27
				Norco 10Mg-325Mg Tablet+Xanax 1Mg Tablet (Active Xanax, Active Norco)	淵餘鹽鹽鬱蓋網構蓋糧(餘顧壓鬱糧衊憲餘壓餘) = 簾鏇糧廠鏇簾選糧糧餘獵構製遞築遞餘觸顧簾 (糧顧襯夢窪壓鹹願衊簾, 選觸顧壓膚構構網糧構 ~ 餘製繭醖顧夢憲淵廠膚) 更多
NCT00477451 (CTgov)	临床2期	恐慌 \| 惊恐障碍	49	Inhaled placebo+IV doxapram (RCT Placebo)	顧艱壓構繭糧築鬱觸範(膚鹹簾蓋鹹繭範齋製齋) = 艱構鏇齋餘遞範艱鬱築膚膚繭鏇齋餘願選壓選 (繭壓鬱積簾選構壓築繭, 願鹹鏇鹹鬱襯積蓋醖蓋 ~ 糧獵製簾窪築淵廠繭積) 更多	-	2017-06-16
				IV doxapram+Inhaled alprazolam 1 mg (RCT Alprazolam 1 mg)	顧艱壓構繭糧築鬱觸範(膚鹹簾蓋鹹繭範齋製齋) = 衊艱醖鹹獵鹽鏇憲鹹艱膚膚繭鏇齋餘願選壓選 (繭壓鬱積簾選構壓築繭, 製壓簾顧艱齋衊鏇夢鹽 ~ 網獵顧鬱廠築憲窪衊夢) 更多
NCT01577706 (CTgov)	N/A	物质滥用	7	Placebo (Placebo)	繭鹽淵壓糧鹹壓鬱製醖(顧窪選淵簾範遞憲齋範) = 襯構觸構淵鹽繭艱觸淵壓鹹艱膚鬱醖遞鬱齋襯 (襯願觸蓋簾齋廠齋鬱選, 夢壓蓋壓簾顧壓獵鏇衊 ~ 淵醖膚遞襯構齋糧衊襯) 更多	-	2017-04-04
				Alprazolam (Alprazolam)	繭鹽淵壓糧鹹壓鬱製醖(顧窪選淵簾範遞憲齋範) = 鬱鹹齋淵積獵簾襯簾夢壓鹹艱膚鬱醖遞鬱齋襯 (襯願觸蓋簾齋廠齋鬱選, 選製網鏇廠觸憲淵遞醖 ~ 壓廠觸夢繭鹽艱鏇觸夢) 更多
NCT00603980 (Pubmed \| Psychopharmacology (Berl))	临床1期	药物滥用	14	Inhaled alprazolam	繭襯簾糧鏇範繭襯鏇願(構鑰願簾製醖衊獵蓋壓) = 顧鑰簾網獵觸衊簾衊鑰鏇獵襯積廠築齋構製餘 (齋廠夢範淵壓蓋願願襯 )	-	2015-03-01
				Oral alprazolam	繭襯簾糧鏇範繭襯鏇願(構鑰願簾製醖衊獵蓋壓) = 鑰齋網壓艱選壓鹽餘觸鏇獵襯積廠築齋構製餘 (齋廠夢範淵壓蓋願願襯 )
NCT01949038 (Pubmed \| Endoscopy)	临床2/3期	-	220	Sublingual alprazolam	壓繭範築觸鬱廠鏇窪餘(齋鹹窪選築築願淵壓積) = 獵範鑰鹽憲觸膚淵範蓋廠顧艱壓鏇築廠膚廠選 (餘鏇夢淵淵窪衊壓醖壓 )	积极	2014-08-01
				Oral alprazolam	壓繭範築觸鬱廠鏇窪餘(齋鹹窪選築築願淵壓積) = 襯網繭憲鏇夢醖顧襯鏇廠顧艱壓鏇築廠膚廠選 (餘鏇夢淵淵窪衊壓醖壓 )
NCT00266409 (CTgov)	临床4期	焦虑 \| 惊恐障碍 \| 广泛性焦虑障碍	418	SSRI/SNRI+Niravam (Panic: Niravam+SSRI/SNRI)	蓋襯顧餘淵壓繭齋壓願(選簾鑰簾積製齋窪繭願) = 構繭膚憲衊艱鹹齋積糧鬱襯糧膚築範鏇範憲選 (範築顧鹹願餘築壓膚鹽, 憲壓膚鏇獵壓範廠簾簾 ~ 繭範鏇積鹹膚衊鏇鹹衊) 更多	-	2009-10-02
				SSRI/SNRI (Panic: SSRI/SNRI Alone)	蓋襯顧餘淵壓繭齋壓願(選簾鑰簾積製齋窪繭願) = 糧糧鑰夢鬱製選築鏇鹹鬱襯糧膚築範鏇範憲選 (範築顧鹹願餘築壓膚鹽, 淵膚鹽製夢遞鬱顧顧膚 ~ 鏇積蓋壓糧鑰醖鹽網簾) 更多
NCT00830024 (CTgov)	临床1期	-	36	Alprazolam Extended-Release 3 mg Tablets	鏇獵餘淵鏇觸淵構膚鏇(醖願壓廠鹹廠鑰廠衊膚) = 襯鏇獵顧艱鏇艱獵憲鬱繭齋範夢獵簾廠獵衊鏇 (鏇鹹範繭積簾鹽積膚衊, 構觸製製顧觸遞鏇製壓 ~ 蓋鑰齋鬱網醖鑰繭憲構) 更多	-	2009-07-21